Westwood Holdings Group Inc. trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 47.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 5,845 shares of the medical research company’s stock after selling 5,275 shares during the period. Westwood Holdings Group Inc.’s holdings in Amgen were worth $1,077,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Marshall Wace LLP bought a new position in Amgen in the 2nd quarter valued at about $4,777,000. Vivaldi Capital Management LLC lifted its position in Amgen by 12.7% in the 2nd quarter. Vivaldi Capital Management LLC now owns 1,786 shares of the medical research company’s stock valued at $329,000 after acquiring an additional 201 shares in the last quarter. Nomura Holdings Inc. lifted its position in Amgen by 137.1% in the 2nd quarter. Nomura Holdings Inc. now owns 7,735 shares of the medical research company’s stock valued at $1,427,000 after acquiring an additional 4,473 shares in the last quarter. Morgan Stanley lifted its position in Amgen by 0.5% in the 2nd quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after acquiring an additional 34,674 shares in the last quarter. Finally, Alberta Investment Management Corp lifted its position in Amgen by 3.3% in the 2nd quarter. Alberta Investment Management Corp now owns 161,000 shares of the medical research company’s stock valued at $29,669,000 after acquiring an additional 5,100 shares in the last quarter. Institutional investors own 76.24% of the company’s stock.

Several equities analysts recently weighed in on AMGN shares. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $220.00 price target (up previously from $202.00) on shares of Amgen in a research report on Tuesday, August 27th. They noted that the move was a valuation call. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Thursday, September 12th. BMO Capital Markets reissued a “buy” rating on shares of Amgen in a research report on Monday, September 9th. JPMorgan Chase & Co. set a $198.00 target price on shares of Amgen and gave the stock a “hold” rating in a research report on Friday, September 6th. Finally, Evercore ISI reissued a “hold” rating on shares of Amgen in a research report on Sunday, August 11th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $217.33.

In other Amgen news, Director R Sanders Williams sold 425 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at $2,990,141.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Cynthia M. Patton sold 13,426 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the completion of the transaction, the senior vice president now owns 32,648 shares in the company, valued at $6,793,069.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,851 shares of company stock worth $3,659,900. 0.25% of the stock is owned by insiders.

Shares of NASDAQ AMGN traded up $1.17 during midday trading on Monday, hitting $198.11. 71,338 shares of the company traded hands, compared to its average volume of 2,712,807. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $211.90. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The stock has a 50-day moving average price of $199.24 and a 200 day moving average price of $185.38. The firm has a market cap of $117.33 billion, a P/E ratio of 13.77, a P/E/G ratio of 2.54 and a beta of 1.11.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating the Zacks’ consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the company posted $3.83 earnings per share. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. As a group, equities analysts expect that Amgen, Inc. will post 14.3 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 6th. Investors of record on Thursday, August 15th were given a dividend of $1.45 per share. The ex-dividend date was Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.93%. Amgen’s dividend payout ratio (DPR) is 40.28%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Holder of Record

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.